<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:51:38Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6104940" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6104940</identifier>
        <datestamp>2018-09-15</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6104940</article-id>
              <article-id pub-id-type="pmcid">PMC6104940</article-id>
              <article-id pub-id-type="pmc-uid">6104940</article-id>
              <article-id pub-id-type="pmid">30133534</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0201952</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-17-30550</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Digestive System</subject>
                      <subj-group>
                        <subject>Gastrointestinal Tract</subject>
                        <subj-group>
                          <subject>Rectum</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Digestive System</subject>
                      <subj-group>
                        <subject>Gastrointestinal Tract</subject>
                        <subj-group>
                          <subject>Rectum</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Interstitial Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Interstitial Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Interstitial Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Interstitial Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmaceutics</subject>
                    <subj-group>
                      <subject>Drug Delivery</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and health sciences</subject>
                  <subj-group>
                    <subject>Infectious diseases</subject>
                    <subj-group>
                      <subject>Viral diseases</subject>
                      <subj-group>
                        <subject>HIV infections</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Medical Microbiology</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Immunodeficiency Viruses</subject>
                            <subj-group>
                              <subject>HIV</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pathology and Laboratory Medicine</subject>
                    <subj-group>
                      <subject>Pathogens</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Immunodeficiency Viruses</subject>
                            <subj-group>
                              <subject>HIV</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>Viral Pathogens</subject>
                        <subj-group>
                          <subject>Immunodeficiency Viruses</subject>
                          <subj-group>
                            <subject>HIV</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>Immunodeficiency Viruses</subject>
                        <subj-group>
                          <subject>HIV</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>RNA viruses</subject>
                        <subj-group>
                          <subject>Retroviruses</subject>
                          <subj-group>
                            <subject>Lentivirus</subject>
                            <subj-group>
                              <subject>HIV</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Medical Microbiology</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Retroviruses</subject>
                            <subj-group>
                              <subject>Lentivirus</subject>
                              <subj-group>
                                <subject>HIV</subject>
                              </subj-group>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pathology and Laboratory Medicine</subject>
                    <subj-group>
                      <subject>Pathogens</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Retroviruses</subject>
                            <subj-group>
                              <subject>Lentivirus</subject>
                              <subj-group>
                                <subject>HIV</subject>
                              </subj-group>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>Viral Pathogens</subject>
                        <subj-group>
                          <subject>Retroviruses</subject>
                          <subj-group>
                            <subject>Lentivirus</subject>
                            <subj-group>
                              <subject>HIV</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Clinical Medicine</subject>
                    <subj-group>
                      <subject>Clinical Trials</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Drug Research and Development</subject>
                      <subj-group>
                        <subject>Clinical Trials</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Clinical Trials</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Pharmacokinetics</subject>
                      <subj-group>
                        <subject>Drug Distribution</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and health sciences</subject>
                  <subj-group>
                    <subject>Clinical medicine</subject>
                    <subj-group>
                      <subject>Clinical trials</subject>
                      <subj-group>
                        <subject>Phase I clinical investigation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and health sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Drug research and development</subject>
                      <subj-group>
                        <subject>Clinical trials</subject>
                        <subj-group>
                          <subject>Phase I clinical investigation</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and analysis methods</subject>
                  <subj-group>
                    <subject>Clinical trials</subject>
                    <subj-group>
                      <subject>Phase I clinical investigation</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc</article-title>
                <alt-title alt-title-type="running-head">Rectal drug exposure from three different intravaginal rings</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3051-9551</contrib-id>
                  <name>
                    <surname>Vincent</surname>
                    <given-names>Kathleen Listiak</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moss</surname>
                    <given-names>John A.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1670-8786</contrib-id>
                  <name>
                    <surname>Marzinke</surname>
                    <given-names>Mark A.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5696-8665</contrib-id>
                  <name>
                    <surname>Hendrix</surname>
                    <given-names>Craig W.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4677-6782</contrib-id>
                  <name>
                    <surname>Anton</surname>
                    <given-names>Peter A.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gunawardana</surname>
                    <given-names>Manjula</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dawson</surname>
                    <given-names>Lauren N.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Olive</surname>
                    <given-names>Trevelyn J.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2215-5500</contrib-id>
                  <name>
                    <surname>Pyles</surname>
                    <given-names>Richard B.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1558-5649</contrib-id>
                  <name>
                    <surname>Baum</surname>
                    <given-names>Marc M.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Visualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Chemistry, Oak Crest Institute of Science, Monrovia, California, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Department of Medicine (Division of Clinical Pharmacology), Johns Hopkins University, Baltimore, Maryland, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Department of Pathology, Johns Hopkins University, Sheikh Zayed Tower, Baltimore, Maryland, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Center for HIV Prevention Research, Division of Digestive Diseases and UCLA AIDS Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, United States of America</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Cressey</surname>
                    <given-names>Timothy R.</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Chiang Mai University, THAILAND</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>I have read the journal's policy and the authors of this manuscript have the following competing interests: KLV and RBP are consultants to ABL, Inc, to expand the ovine preclinical model; this was disclosed to UTMB Conflict of Interest, with money paid directly to KLV and RBP. CWH declares current financial interests in NIH, Gates, and Viiv/GSK funding for clinical research managed through employer (Johns Hopkins University). CWH was a consultant for 1-2 days in the past year to ViiV/GSK for product development of potentially competing product application; this was disclosed to Johns Hopkins Conflict of Interest, money paid directly to CWH. CWH is a current consultant to UCLA scientists for product development of potentially competing product application; this was disclosed to Johns Hopkins Conflict of Interest, money paid directly to CWH. JAM and MMB declare a paid salary for full time employment as faculty members at the Oak Crest Institute of Science. As faculty members JAM and MMB are investigators (NIH U19 Program) on research grants to Oak Crest from the National Institutes of Health (NIH) that funded the research in this manuscript. Additionally, as a faculty members, JAM and MMB are/were principal investigators or co-investigators on grants that funded other research into HIV prevention and intravaginal ring/subdermal implant drug delivery. The research grants not directly related to the research that is the subject of this manuscript were funded by NIH, International Partnership for Microbicides, and USAID (funding through the Population Council). Oak Crest receives funding for research in which JAM and MMB are participants. JAM and MMB are also co-inventors on patent applications that include aspects of the intravaginal ring device that was used in the clinical trial described in this manuscript. The following authors are former salaried employees of Auritec Pharmaceuticals, Inc.: IB, SAC, JMC Jr., and MG. During time of the study, IB and JMC Jr were employees of Auritec and participated in manufacturing the vaginal rings. Prior to August 2016, MG was a 50/50 shared employee for both Oak Crest and Auritec. SAC later performed CVL analysis as an Oak Crest employee. They were no longer employees during sample/data analysis and manuscript preparation. None of these authors have ownership of Auritec stocks or shares, hold Auritec Board membership, or are senior personnel on Auritec research grants. MG is an inventor on active patent applications as an Oak Crest employee. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>klvincen@UTMB.EDU</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>8</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2018</year>
              </pub-date>
              <volume>13</volume>
              <issue>8</issue>
              <elocation-id>e0201952</elocation-id>
              <history>
                <date date-type="received">
                  <day>18</day>
                  <month>8</month>
                  <year>2017</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>5</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2018 Vincent et al</copyright-statement>
                <copyright-year>2018</copyright-year>
                <copyright-holder>Vincent et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0201952.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>Intravaginal rings (IVRs) can deliver antiretroviral (ARV) agents for HIV pre-exposure prophylaxis (PrEP), theoretically overcoming adherence concerns associated with frequent dosing. However, topical vaginal ARV drug delivery has not simultaneously led to sufficient rectal drug exposure to likely protect from HIV infection as a result of receptive anal intercourse (RAI). Unprotected RAI has a higher risk of infection per sex act and, for women, also can be associated with vaginal exposure during a single sexual encounter, especially in higher-risk subsets of women. The physiologically inflamed, activated, immune-cell dense colorectal mucosa is increasingly appreciated as the sexual compartment with highly significant risk; this risk is increased in the setting of co-infections. <italic>Ex vivo</italic> studies have shown that colorectal tissue and rectal fluid concentrations correlated with HIV protection. Given these important results, efforts to document colorectal compartment ARV drug concentration from pod-IVR delivery was assessed to determine if vaginal application could provide protective ARV levels in both compartments.</p>
                </sec>
                <sec id="sec002">
                  <title>Methodology/Principal findings</title>
                  <p>A crossover clinical trial (<italic>N</italic> = 6) evaluated 7 d of continuous TDF pod-IVR use, a wash-out phase, followed by 7 d with a TDF-FTC pod-IVR. A subsequent clinical trial (<italic>N</italic> = 6) consisted of 7 d of continuous TDF-FTC-MVC pod-IVR use. Rectal fluids were collected on Day 7 at IVR removal in all three ARV-exposures (two Phase 1 trials) and drug concentrations quantified by LC-MS/MS.</p>
                  <p>Median rectal fluid concentrations of TFV, the hydrolysis product of the prodrug TDF, were between 0.66 ng mg<sup>-1</sup> (TDF pod-IVR group) and 1.11 ng mg<sup>-1</sup> (TDF-FTC pod-IVR group), but below the analytical lower limit of quantitation in 5/6 samples in the TDF-FTC-MVC pod-IVR group. Unexpectedly, median FTC (TDF-FTC pod-IVR, 20.3 ng mg<sup>-1</sup>; TDF-FTC-MVC pod-IVR, 0.18 ng mg<sup>-1</sup>), and MVC rectal fluid concentrations (0.84 ng mg<sup>-1</sup>) were quantifiable and higher than their respective <italic>in vitro</italic> EC<sub>50</sub> values in most samples. Due to participant burden in these exploratory trials, rectal fluid was used as a surrogate for rectal tissue, where drug concentrations are expected to be higher.</p>
                </sec>
                <sec id="sec003">
                  <title>Conclusions/Significance</title>
                  <p>The concentrations of FTC and MVC in rectal fluids obtained in two exploratory clinical trials of IVRs delivering ARV combinations exceeded levels associated with <italic>in vitro</italic> efficacy in HIV inhibition. Unexpectedly, MVC appeared to depress the distribution of TFV and FTC into the rectal lumen. Here we show that vaginal delivery of ARV combinations may provide adherence and coitally independent dual-compartment protection from HIV infection during both vaginal and receptive anal intercourse.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009633</institution-id>
                      <institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R44HD075636</award-id>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U19AI113048</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1558-5649</contrib-id>
                    <name>
                      <surname>Baum</surname>
                      <given-names>Marc M.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006108</institution-id>
                      <institution>National Center for Advancing Translational Sciences</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>UL1 TR001439</award-id>
                </award-group>
                <award-group id="award004">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006108</institution-id>
                      <institution>National Center for Advancing Translational Sciences</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>UL1 TR001079</award-id>
                </award-group>
                <award-group id="award005">
                  <funding-source>
                    <institution>Johns Hopkins Center for AIDS Research</institution>
                  </funding-source>
                  <award-id>P30AI094189</award-id>
                </award-group>
                <funding-statement>This work was funded by: The Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development of the National Institutes of Health (<ext-link ext-link-type="uri" xlink:href="https://www.nichd.nih.gov/Pages/index.aspx">https://www.nichd.nih.gov/Pages/index.aspx</ext-link> Award Number R44HD075636); National Institute of Allergy and Infectious Diseases of the National Institutes of Health (<ext-link ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/">https://www.niaid.nih.gov/</ext-link> Award Number U19AI113048, MMB); Institute for Translational Sciences at the University of Texas Medical Branch, from the National Center for Advancing Translational Sciences, National Institutes of Health (<ext-link ext-link-type="uri" xlink:href="https://ncats.nih.gov/">https://ncats.nih.gov/</ext-link> Award number UL1 TR001439); Institute for Clinical and Translational Research (ICTR) at Johns Hopkins University, from the National Center for Advancing Translational Sciences, National Institutes of Health (<ext-link ext-link-type="uri" xlink:href="https://ncats.nih.gov/">https://ncats.nih.gov/</ext-link> Award Number UL1 TR001079); and Johns Hopkins Center for AIDS Research (<ext-link ext-link-type="uri" xlink:href="http://hopkinscfar.org/">http://hopkinscfar.org/</ext-link> Award Number P30AI094189). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Auritec Pharmaceuticals, Inc. was the sponsor of the study and prime recipient of the NIH grant (Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development of the National Institutes of Health under Award Number R44HD075636) that funded part of the study. Auritec played a role in study design, but had a limited role in data collection and analysis, and no role in preparation of the manuscript. Study materials (e.g., IVRs) were provided to UTMB (clinical site) by Oak Crest in collaboration with Auritec.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="2"/>
                <page-count count="12"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the paper and its Supporting Information files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec004">
              <title>Introduction</title>
              <p>Topical dosing of antiretroviral (ARV) agents using products formulated for rectal or vaginal application have the potential of protecting against sexually transmitted infections, including HIV. Intravaginal rings (IVRs) can deliver antiretroviral (ARV) agents for HIV pre-exposure prophylaxis (PrEP) [<xref rid="pone.0201952.ref001" ref-type="bibr">1</xref>–<xref rid="pone.0201952.ref003" ref-type="bibr">3</xref>], theoretically overcoming adherence concerns associated with frequent dosing [<xref rid="pone.0201952.ref004" ref-type="bibr">4</xref>]. We have developed an innovative IVR technology, the pod-IVR [<xref rid="pone.0201952.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0201952.ref005" ref-type="bibr">5</xref>], that enables accelerated development of products capable of delivering multiple agents over a wide range of aqueous solubilities and target delivery rates into the cervicovaginal compartment [<xref rid="pone.0201952.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0201952.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0201952.ref006" ref-type="bibr">6</xref>–<xref rid="pone.0201952.ref008" ref-type="bibr">8</xref>].</p>
              <p>We have evaluated the clinical pharmacokinetics (PKs) and safety of pod-IVRs delivering the nucleoside reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) alone and in combination with emtricitabine (FTC) [<xref rid="pone.0201952.ref009" ref-type="bibr">9</xref>], another NRTI. We subsequently conducted a clinical trial with the first triple combination ARV pod-IVR simultaneously delivering TDF, FTC, and maraviroc (MVC), an inhibitor/antagonist of chemokine receptor CCR5 [<xref rid="pone.0201952.ref009" ref-type="bibr">9</xref>].</p>
              <p>Topical vaginal ARV drug delivery has not been well-evaluated to determine if this route of administration could lead to simultaneous rectal drug exposure sufficient to protect from HIV infection as a result of receptive anal intercourse (RAI) [<xref rid="pone.0201952.ref010" ref-type="bibr">10</xref>–<xref rid="pone.0201952.ref014" ref-type="bibr">14</xref>]. Exposure through RAI has a higher risk of infection per sex act and, for women, especially those in higher-risk subsets, there is the possibility of both vaginal and rectal exposure during a single sex act [<xref rid="pone.0201952.ref015" ref-type="bibr">15</xref>–<xref rid="pone.0201952.ref017" ref-type="bibr">17</xref>]. The physiologically inflamed, activated, immune-cell dense colorectal mucosa is increasingly appreciated as the sexual compartment with highly significant risk. <italic>Ex vivo</italic> HIV challenge of colorectal biopsies from humans receiving oral, vaginal, and rectal ARV drugs have demonstrated suppression of HIV infection, sometimes with clear concentration-response relationships [<xref rid="pone.0201952.ref018" ref-type="bibr">18</xref>–<xref rid="pone.0201952.ref026" ref-type="bibr">26</xref>].</p>
              <p>The risk of HIV acquisition associated with both vaginal and rectal sexual intercourse, along with the above results informing potential efficacious ARV drug concentrations needed for rectal protection, have led us to collect rectal fluids in the above clinical trials evaluating pod-IVRs delivering TDF, TDF-FTC, and TDF-FTC-MVC. Colorectal compartment drug concentrations are assessed here to determine if vaginal application could simultaneously provide protective ARV levels in both compartments.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec005">
              <title>Materials and methods</title>
              <sec id="sec006">
                <title>Ethics statement</title>
                <p>All human research was approved by the University of Texas Medical Branch Institutional Review Board (IRB # 14–0479), conducted according to the Declaration of Helsinki, and registered in clinicaltrials.gov (NCT02431273; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02431273?term=NCT02431273&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02431273?term=NCT02431273&amp;rank=1</ext-link>). All participants provided written informed consent.</p>
              </sec>
              <sec id="sec007">
                <title>Clinical trial design</title>
                <p>The early Phase I clinical studies were performed between June 2015 and July 2016 at the Clinical Research Center of the University of Texas Medical Branch in Galveston, Texas. Women were recruited by announcements and word of mouth and underwent a phone pre-screen prior to attending a screening visit where informed consent was obtained and inclusion/exclusion criteria were confirmed. Inclusion criteria included age 18–45, regular menstrual cycles, use of contraception, and agreement to abstain from sexual intercourse during use of the IVR until the follow up exam 1–2 weeks after discontinuation of IVR use. Exclusion criteria included HIV, Heptatitis B, or sexually transmitted disease (gonorrhea, chlamydia, trichomonas) at the time of screening, abnormal liver or kidney function tests, and pregnancy/lactation.</p>
                <p>Women initially participated in a clinical trial where they used a pod-IVR releasing TDF and a TDF-FTC combination for 7 days in a cross-over, open label design, with at least 2 weeks of washout between IVRs (<italic>n</italic> = 6) (<xref ref-type="fig" rid="pone.0201952.g001">Fig 1</xref>) [<xref rid="pone.0201952.ref009" ref-type="bibr">9</xref>]. After the study team ensured that the IVRs were safe and provided adequate drug release, the women were invited to re-screen for a continuation of the study where they used a pod-IVR releasing the TDF-FTC-MVC combination for 7 days in an open label design, with new subjects additionally recruited in order to enroll a total of 6 women to use this IVR (<xref ref-type="fig" rid="pone.0201952.g001">Fig 1</xref>) [<xref rid="pone.0201952.ref009" ref-type="bibr">9</xref>]. In all three arms, vaginal fluid (Dacron swab), vaginal biopsy, and rectal fluid (Dacron swab) samples were collected on Day 7, immediately after IVR removal. Rectal biopsies were not acquired during these studies due to the increased participant burden. [<xref rid="pone.0201952.ref020" ref-type="bibr">20</xref>]</p>
                <fig id="pone.0201952.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0201952.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Participant flow diagram.</title>
                  </caption>
                  <graphic xlink:href="pone.0201952.g001"/>
                </fig>
              </sec>
              <sec id="sec008">
                <title>Chemicals, reagents, and fabrication of pod-IVRs</title>
                <p>Materials and methods related to the IVR fabrication have been provided elsewhere [<xref rid="pone.0201952.ref009" ref-type="bibr">9</xref>] Briefly, TDF and FTC (labeled for human use) were purchased from commercial vendors with a Drug Master File (DMF) registered with the FDA. MVC was isolated from the commercial formulation (Pfizer, Inc., New York, NY), which consists of film-coated tablets for oral administration containing 300 mg of MVC and inactive ingredients, as described previously [<xref rid="pone.0201952.ref002" ref-type="bibr">2</xref>]. All other reagents were obtained from Sigma-Aldrich, unless otherwise noted.</p>
                <p>Polydimethylsiloxane (PDMS, silicone) pod-IVRs were fabricated has according to methods described in detail elsewhere [<xref rid="pone.0201952.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0201952.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0201952.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0201952.ref027" ref-type="bibr">27</xref>]. The IVR drug content was as follows: TDF, 180 mg; FTC, 135 mg; MVC, 90 mg. The amount of residual drug remaining in used IVRs was measured by HPLC according to published methods [<xref rid="pone.0201952.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0201952.ref027" ref-type="bibr">27</xref>].</p>
              </sec>
              <sec id="sec009">
                <title>Bioanalysis of <italic>in vivo</italic> samples</title>
                <p>Concentrations of TDF, TFV, TFV-DP, FTC, and MVC in fluids/tissue were determined <italic>via</italic> previously described liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assays [<xref rid="pone.0201952.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0201952.ref028" ref-type="bibr">28</xref>–<xref rid="pone.0201952.ref030" ref-type="bibr">30</xref>]. All assays were developed and validated following the Food and Drug Administration Guidance for Industry, Bioanalytical Method Validation recommendations and met all acceptability criteria [<xref rid="pone.0201952.ref031" ref-type="bibr">31</xref>]. Isotopically labeled internal standards were used for all compounds and the determination of drug concentrations in all specimen sources.</p>
                <p>The lower limits of quantification for these methods were as follows: cervicovaginal fluids (CVFs), TDF (0.0625 ng/sample), TFV (0.25 ng/sample), FTC (1.0 ng/sample), MVC (0.05 ng/sample); vaginal tissue homogenate, TFV (0.05 ng/sample), FTC (0.25 ng/sample), MVC (0.05 ng/sample); rectal fluids, TFV (0.25 ng/sample), FTC (1.0 ng/sample), MVC (0.05 ng/sample). Drug concentrations in luminal fluid and tissue samples were ultimately reported as ng mg<sup>-1</sup> or fmol mg<sup>-1</sup>, respectively, following normalization to net biopsy or Dacron swab weight. Post-dose concentrations below the corresponding LLOQs (<italic>C</italic><sub><italic>LLQ</italic></sub>) were imputed as follows in all analyses:
<disp-formula id="pone.0201952.e001"><alternatives><graphic xlink:href="pone.0201952.e001.jpg" id="pone.0201952.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">LLQ</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">LLOQ</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">assay</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mo>(</mml:mo><mml:mi mathvariant="normal">median</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">sample</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">mass</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></alternatives></disp-formula></p>
                <p>Results included here to provide intra-subject and between-group context for interpreting the comparative utility of rectal fluid results necessarily include CVF and VT concentration data from these trials that was also published separately [<xref rid="pone.0201952.ref009" ref-type="bibr">9</xref>].</p>
              </sec>
              <sec id="sec010">
                <title>Statistical analysis</title>
                <p>Data were analyzed using GraphPad Prism (version 7.00, GraphPad Software, Inc., La Jolla, CA). Statistical significance is defined as <italic>P</italic> &lt; 0.05.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec011">
              <title>Results</title>
              <p>Details on IVR safety, drug concentrations in vaginal fluid and tissue, and user perception have been provided elsewhere [<xref rid="pone.0201952.ref009" ref-type="bibr">9</xref>]. In brief, no significant AEs or behavioral concerns were identified with use of any of the pod-IVRs. All participants completed all study visits and there were no missed visits, drop-outs, or loss to follow-up (<xref ref-type="fig" rid="pone.0201952.g001">Fig 1</xref>).</p>
              <sec id="sec012">
                <title>Drug concentration measurements</title>
                <p>Drug concentrations in key anatomic compartments on Day 7 are summarized in <xref rid="pone.0201952.t001" ref-type="table">Table 1</xref> and <xref ref-type="fig" rid="pone.0201952.g002">Fig 2A</xref>. All Rectal fluid TFV concentrations resulting from either the TDF or the TDF-FTC pod-IVRs were not significantly different (<italic>P</italic> = 0.20), using a two-tailed paired <italic>t</italic> test. While important on its own, rectal fluid TFV concentrations in the TDF-FTC-MVC group was quantifiable in only one out of six samples (<xref rid="pone.0201952.t001" ref-type="table">Table 1</xref>). Rectal fluid FTC concentrations resulting from either the TDF-FTC or the TDF-FTC-MVC pod-IVRs were not significantly different (<italic>P</italic> = 0.10), using an unpaired <italic>t</italic> test with Welch’s correction (i.e., do not assume equal standard deviations). While TFV concentrations in rectal fluid were similar in the TDF (median, 0.62 ng mg<sup>-1</sup>; IQR, 0.30–0.81 ng mg<sup>-1</sup>) and TDF-FTC (median, 1.11 ng mg<sup>-1</sup>; IQR, 0.36–2.15 ng mg<sup>-1</sup>) groups, median FTC concentrations in rectal fluid in the TDF-FTC (median, 20.3 ng mg<sup>-1</sup>; IQR, 14.0–28.9 ng mg<sup>-1</sup>) group were 190 times higher than in the TDF-FTC-MVC (median, 0.11 ng mg<sup>-1</sup>; IQR, 0.04–0.22 ng mg<sup>-1</sup>) group.</p>
                <fig id="pone.0201952.g002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0201952.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Rectal fluid ARV drug exposure and distribution following IVR delivery.</title>
                    <p>Every circular datum represents an individual sample from one of the participants (<italic>n</italic> = 6); horizontal lines represent group medians; blue, TFV; red, FTC; green, MVC. (A) rectal fluid drug concentrations on Day 7. Paired Day 7 concentration ratios across anatomic compartments provide a measure of drug distribution; (B) cervicovaginal fluid to vaginal tissue (CVF:VT), with two VT MVC samples omitted as these were ALQ; (C) vaginal tissue to rectal fluid (VT:RF); (D) cervicovaginal fluid to rectal fluid (CVF:RF). Triangles represent samples where the rectal fluid drug concentration was BLQ.</p>
                  </caption>
                  <graphic xlink:href="pone.0201952.g002"/>
                </fig>
                <table-wrap id="pone.0201952.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0201952.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Summary of drug concentrations in key anatomic compartments on Day 7, immediately after pod-IVR removal (six participants in each group).</title>
                    <p>CVF, cervicovaginal fluid; VT, vaginal tissue; RF, rectal fluid. Measurements outside of the analytical ranges were not included in the analysis.</p>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0201952.t001g" xlink:href="pone.0201952.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="center" colspan="3" rowspan="1">Pod-IVR Type<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref></th>
                        </tr>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Analyte, matrix</th>
                          <th align="left" rowspan="1" colspan="1">TDF</th>
                          <th align="left" rowspan="1" colspan="1">TDF-FTC</th>
                          <th align="left" rowspan="1" colspan="1">TDF-FTC-MVC</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Total TFV,<xref ref-type="table-fn" rid="t001fn002"><sup>b</sup></xref> CVF, ng mg<sup>-1</sup></td>
                          <td align="left" rowspan="1" colspan="1">51.3 (34.8–61.5)</td>
                          <td align="left" rowspan="1" colspan="1">40.8 (28.9–49.1)</td>
                          <td align="left" rowspan="1" colspan="1">67.4 (43.4–72.1)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">FTC, CVF, ng mg<sup>-1</sup></td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">1,458 (881–2,073)</td>
                          <td align="left" rowspan="1" colspan="1">839 (818–1,572)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MVC, CVF, ng mg<sup>-1</sup></td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">367 (224–489)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">TFV, VT <xref ref-type="table-fn" rid="t001fn003"><sup>c</sup></xref>, ng mg<sup>-1</sup></td>
                          <td align="left" rowspan="1" colspan="1">8.4 (4.7–11.2)</td>
                          <td align="left" rowspan="1" colspan="1">5.1 (0.77–10.1)</td>
                          <td align="left" rowspan="1" colspan="1">5.1 (3.3–9.7)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">FTC, VT <xref ref-type="table-fn" rid="t001fn003"><sup>c</sup></xref>, ng mg<sup>-1</sup></td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">74.5 (11.6–193)</td>
                          <td align="left" rowspan="1" colspan="1">104 (63.7–302)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MVC, VT <xref ref-type="table-fn" rid="t001fn003"><sup>c</sup></xref>, ng mg<sup>-1</sup></td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">142 (82.5–212)<xref ref-type="table-fn" rid="t001fn004"><sup>d</sup></xref></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">TFV, RF, ng mg<sup>-1</sup></td>
                          <td align="left" rowspan="1" colspan="1">0.62 (0.30–0.81)<xref ref-type="table-fn" rid="t001fn005"><sup>e</sup></xref></td>
                          <td align="left" rowspan="1" colspan="1">1.11 (0.36–2.15)</td>
                          <td align="left" rowspan="1" colspan="1">0.004<xref ref-type="table-fn" rid="t001fn006"><sup>f</sup></xref></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">FTC, RF, ng mg<sup>-1</sup></td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">20.3 (14.0–28.9)</td>
                          <td align="left" rowspan="1" colspan="1">0.11 (0.04–0.22)<xref ref-type="table-fn" rid="t001fn007"><sup>g</sup></xref></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MVC, RF, ng mg<sup>-1</sup></td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">0.84 (0.32–1.10)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p><sup>a</sup>Median (Interquartile range, 25th to 75th percentile).</p>
                    </fn>
                    <fn id="t001fn002">
                      <p><sup>b</sup>Molar sum of paired TDF and TFV concentrations, reported as TFV.</p>
                    </fn>
                    <fn id="t001fn003">
                      <p><sup>c</sup>Used with permission [<xref rid="pone.0201952.ref009" ref-type="bibr">9</xref>]</p>
                    </fn>
                    <fn id="t001fn004">
                      <p><sup>d</sup>33% of samples above the analytical quantification limit.</p>
                    </fn>
                    <fn id="t001fn005">
                      <p><sup>e</sup>83% of samples were above the analytical LLQ.</p>
                    </fn>
                    <fn id="t001fn006">
                      <p><sup>f</sup>Only one sample was above the analytical LLQ.</p>
                    </fn>
                    <fn id="t001fn007">
                      <p><sup>g</sup>67% of samples were above the analytical LLQ.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>The collection and analysis of cervicovaginal fluid (CVF), vaginal tissue (VT), and rectal fluid (RF) samples from all six study participants allows paired drug concentration ratios (i.e., CVF:VT, VT:RF, and CVF:RF) to be compared across all three compartments in <xref rid="pone.0201952.t002" ref-type="table">Table 2</xref> and <xref ref-type="fig" rid="pone.0201952.g002">Fig 2B and 2C</xref>. The TFV CVF:VT ratios across all three groups were compared with a nonparametric, Kruskal-Wallis test and determined not to be significantly different (<italic>P</italic> = 0.85). The FTC CVF:VT ratios in the TDF-FTC and TDF-FTC-MVC pod-IVR groups also were not significantly different (<italic>P</italic> = 0.26), using an unpaired <italic>t</italic> test with Welch’s correction.</p>
                <table-wrap id="pone.0201952.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0201952.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Paired drug concentration ratios by anatomic compartment on Day 7, immediately after pod-IVR removal (six participants in each group).</title>
                    <p>CVF, cervicovaginal fluid; VT, vaginal tissue; RF, rectal fluid. Data consist of medians (interquartile range) and only measurements within the analytical range of the assay are included.</p>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0201952.t002g" xlink:href="pone.0201952.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="center" colspan="3" rowspan="1">Pod-IVR Type</th>
                        </tr>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Analyte, Ratio</th>
                          <th align="left" rowspan="1" colspan="1">TDF</th>
                          <th align="left" rowspan="1" colspan="1">TDF-FTC</th>
                          <th align="left" rowspan="1" colspan="1">TDF-FTC-MVC</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">TFV,<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref> CVF:VT</td>
                          <td align="left" rowspan="1" colspan="1">6.6 (4.5–8.8)</td>
                          <td align="left" rowspan="1" colspan="1">14 (4.2–42)</td>
                          <td align="left" rowspan="1" colspan="1">14 (6.0–17)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">FTC, CVF:VT</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">17 (8.6–67)</td>
                          <td align="left" rowspan="1" colspan="1">12 (5.8–17)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MVC, CVF:VT</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">3.5 (1.2–6.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">TFV, VT:RF</td>
                          <td align="left" rowspan="1" colspan="1">20 (17–20)</td>
                          <td align="left" rowspan="1" colspan="1">6.2 (3.4–19)</td>
                          <td align="left" rowspan="1" colspan="1">946 (559–2,396)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">FTC, VT:RF</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">5.6 (1.3–12)</td>
                          <td align="left" rowspan="1" colspan="1">1,702 (404–3,565)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MVC, VT:RF</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">423 (101–855)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">TFV,<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref> CVF:RF</td>
                          <td align="left" rowspan="1" colspan="1">87 (67–145)</td>
                          <td align="left" rowspan="1" colspan="1">63 (25–100)</td>
                          <td align="left" rowspan="1" colspan="1">12,763 (8,835–16,813)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">FTC, CVF:RF</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">83 (75–111)</td>
                          <td align="left" rowspan="1" colspan="1">7,181 (6,978–40,726)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MVC, CVF:RF</td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">644 (228–950)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p><sup>a</sup>Molar sum of paired TDF and TFV concentrations in CVF, reported as TFV.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Tenofovir VT:RF ratios in the TDF (median, 20; IQR, 17–20) group were numerically 3.2 times higher than in the TDF-FTC (median, 6.2; IQR, 3.4–19) group, and 47 times lower than in the TDF-FTC-MVC (median, 946; IQR, 559–2,396) group, where most measurements were BLQ. Emtricitabine VT:RF ratios in the TDF-FTC (median, 5.6; IQR, 1.3–12) group were 304 times lower overall than in the TDF-FTC-MVC (median, 1,702; IQR, 404–3,565) group. However, with the small sample size, the VT:RF ratios were not significantly different for TFV (<italic>P</italic> = 0.31) in the TDF and TDF-FTC pod-IVR groups and for FTC (<italic>P</italic> = 0.24) in the TDF-FTC and TDF-FTC-MVC pod-IVR groups, using an unpaired <italic>t</italic> test with Welch’s correction.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec013">
              <title>Discussion</title>
              <p>Antiretroviral drug concentrations in rectal fluids were higher than expected following pod-IVR (i.e., vaginal) drug delivery in all three clinical trial arms. Tenofovir RF concentrations in the TDF (median, 0.62 ng mg<sup>-1</sup>; IQR, 0.30–0.81 ng mg<sup>-1</sup>) and TDF-FTC groups (median, 1.11 ng mg<sup>-1</sup>; IQR, 0.36–1.25 ng mg<sup>-1</sup>) were comparable to those reported on Day 7 in another clinical trial (median, 0.44 ng mg<sup>-1</sup>; IQR, 0.22–1.94 ng mg<sup>-1</sup>) evaluating a reservoir TDF IVR [<xref rid="pone.0201952.ref014" ref-type="bibr">14</xref>]. Our Day 7 TFV CVF:RF concentration ratios (<xref rid="pone.0201952.t002" ref-type="table">Table 2</xref>, <xref ref-type="fig" rid="pone.0201952.g001">Fig 1D</xref>) in the TDF (median, 87; IQR, 67–145) and TDF-FTC groups (median, 63; IQR, 25–100) were lower than the corresponding ratios measured on Day 7 (median, 104; IQR, 59–505) in the clinical study involving the reservoir TDF IVR [<xref rid="pone.0201952.ref014" ref-type="bibr">14</xref>]. The lowest rectal fluid drug exposure was obtained with TFV, especially in the TDF-FTC-MVC group where only one of six samples was above the lower limit of quantitation of the assay.</p>
              <p>In MTN-001, the pharmacokinetics of a 1% TFV (note, not TDF) vaginal gel were evaluated in a randomized, cross-over study involving 144 HIV-uninfected women, of which a subset of 12 had rectal sampling [<xref rid="pone.0201952.ref011" ref-type="bibr">11</xref>]. Comparing the end-of-period visit measurements of median CVF (3.1×10<sup>3</sup> ng mg<sup>-1</sup>, estimated from CVL samples assuming a 20-fold dilution of the CVF) and RF (6.0 ng mg<sup>-1</sup>, estimated from rectal sponge measurements reported in ng/sponge and a median mass of rectal fluid collected of 20 mg) concentrations affords a median CFV:RF TFV concentration ratio of 517. In MTN-014, 14 HIV-uninfected women received daily vaginal TFV 1% (reduced glycerin formulation) gel for 2 weeks. The median TFV concentration in CVF swabs (7,138 ng/swab) and RF swabs (4.4 ng/swab) indicate a CVF:RF TFV ratio of ca. 1,622 [<xref rid="pone.0201952.ref013" ref-type="bibr">13</xref>]. Taken together, these two TFV vaginal gel dosing studies report CVF:RF TFV ratios roughly 10–25 times higher than those measured with our pod-IVR. The lower the CFV:RF concentration ratio, the more efficiently the drug is thought to partition from the vaginal to rectal lumen. Clinical data on vaginal to rectal drug distribution for FTC and MVC are not available outside of the current report.</p>
              <p>The RF ARV exposure measured here following vaginal drug delivery may hold important implications for HIV PrEP efficacy following receptive anal intercourse (RAI). While EC<sub>50</sub>, or EC<sub>90</sub>, drug concentrations are not used here as target concentrations for HIV prevention, they provide a preliminary guide to gauge possible efficacy. The <italic>in vitro</italic> EC<sub>50</sub> of TFV against HIV-1 was 0.18 μM in peripheral blood mononuclear cells (PBMCs) [<xref rid="pone.0201952.ref032" ref-type="bibr">32</xref>] and 0.5 μM in MT-2 cells [<xref rid="pone.0201952.ref033" ref-type="bibr">33</xref>]. Median <italic>in vivo</italic> TFV RF concentrations in the TDF and TDF-FTC pod-IVR groups were ca. 3.5 μM (1 ng mg<sup>-1</sup>), in the range currently thought to be needed to provide some level of protection from HIV infection. Median FTC RF concentrations in the TDF-FTC pod-IVR group (20 ng mg<sup>-1</sup>, 81 μM) and in the TDF-FTC-MVC pod-IVR group (0.11 ng mg<sup>-1</sup>, 0.43 μM) compare favorably to the range of EC<sub>50</sub> (1×10<sup>−3</sup>–0.64 μM) and EC<sub>90</sub> concentrations (0.06–0.35 μM) against HIV reported for a variety of <italic>in vitro</italic> assays [<xref rid="pone.0201952.ref034" ref-type="bibr">34</xref>–<xref rid="pone.0201952.ref038" ref-type="bibr">38</xref>]. Median <italic>in vivo</italic> MVC RF concentrations (0.84 ng mg<sup>-1</sup>, 1.6 μM) measured here were conservatively higher than the <italic>in vitro</italic> anti-HIV EC<sub>50</sub> (0.1×10<sup>−3</sup>–6×10<sup>−3</sup> μM) and EC<sub>90</sub> concentrations (0.5×10<sup>−3</sup>–0.013 μM) reported in the literature [<xref rid="pone.0201952.ref037" ref-type="bibr">37</xref>, <xref rid="pone.0201952.ref039" ref-type="bibr">39</xref>].</p>
              <p>The above preliminary analysis suggests that dual compartment protection from HIV infection may be possible with combination pod-IVRs, with the following important caveats. First, adding MVC to the TDF-FTC combination was associated with a decrease in measurable levels of TFV and FTC in rectal fluids (<xref ref-type="fig" rid="pone.0201952.g002">Fig 2A</xref>), despite similar concentrations of TDF/TFV and FTC across groups in CFV and VT (<xref rid="pone.0201952.t001" ref-type="table">Table 1</xref>). While these two drugs work intracellularly in target cells, underscoring the importance of direct tissue measurements, the underlying mechanism for TFV and FTC RF reductions in the presence of vaginally-administered MVC is unknown, but could involve changes in molecular transporter expression [<xref rid="pone.0201952.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0201952.ref041" ref-type="bibr">41</xref>], or transporter inhibition, in the rectovaginal septum (i.e., layer of tissue between the vagina and the rectum). Second, colorectal tissue, not the lumen, is the likely pharmacologic compartment determining HIV PrEP efficacy.</p>
              <p>While ARV drug concentrations in rectal tissues were not measured here, the drug concentration ratios across compartments (<xref rid="pone.0201952.t002" ref-type="table">Table 2</xref>, <xref ref-type="fig" rid="pone.0201952.g001">Fig 1B–1D</xref>) suggest that the agents distribute across the rectovaginal septum, rather first than through systemic circulation on the way to the rectal tissue. This hypothesis suggests that anterior (i.e., closer in proximity to the vagina) colorectal tissue drug concentrations will be higher than in rectal fluids, which in turn may exceed posterior colorectal tissue drug concentrations. It is theoretically possible that vaginal to rectal drug distribution could occur through a combination passive and active transport along with local venous and lymphatic drainage. The luminal and mucosal colorectal drug distribution is critical in determining potential efficacy in HIV prevention, as discussed in Weld <italic>et al</italic>. [<xref rid="pone.0201952.ref042" ref-type="bibr">42</xref>], and needs to be studied further in future pod-IVR trials. Topical dosing has the advantage of producing very high local drug concentrations that may be sufficient to achieve diffusion to a second compartment such that, even with a steep concentration gradient, a protective level might be obtained, especially if activation of the drug is different in the second compartment. For example, colon <italic>versus</italic> cervicovaginal intracellular phosphorylation differences could completely compensate for diffusion-dependent concentration gradients of the parent drug by producing more phosphorylated TFV or FTC in the second compartment.</p>
              <p>In conclusion, rectal fluid ARV drug concentrations resulting from vaginal dosing using three different pod-IVR formulations were detectable and, higher than anticipated. The results suggest that dual compartment protection from sexual HIV infection may be possible while maintaining a low systemic drug exposure. These important findings warrant further investigation in larger clinical trials.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec014">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0201952.s001">
                <label>S1 Fig</label>
                <caption>
                  <title>TREND Statement checklist.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0201952.s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0201952.s002">
                <label>S1 Text</label>
                <caption>
                  <title>Protocol summary.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0201952.s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0201952.s003">
                <label>S1 Table</label>
                <caption>
                  <title>Drug concentrations in rectal fluid samples collected on the day of TDF pod-IVR removal (six participants); i.e., Day 7.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0201952.s003.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0201952.s004">
                <label>S2 Table</label>
                <caption>
                  <title>Drug concentrations in rectal fluid samples collected on the day of TDF-FTC pod-IVR removal (six participants); i.e., Day 7.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0201952.s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0201952.s005">
                <label>S3 Table</label>
                <caption>
                  <title>Drug concentrations in rectal fluid samples collected on the day of TDF-FTC-MVC pod-IVR removal (six participants); i.e., Day 7.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0201952.s005.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>Research reported in this publication was supported in part by Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development of the National Institutes of Health under Award Number R44HD075636 and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U19AI113048. Additionally, this study was conducted with the support of the Institute for Translational Sciences at the University of Texas Medical Branch and by the Institute for Clinical and Translational Research (ICTR) at Johns Hopkins University, supported in part by Clinical and Translational Science Awards (UL1 TR001439 and UL1 TR001079, respectively) from the National Center for Advancing Translational Sciences, National Institutes of Health and by the Johns Hopkins Center for AIDS Research (P30AI094189). The funders did not play a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0201952.ref001">
                <label>1</label>
                <mixed-citation publication-type="book"><name><surname>Moss</surname><given-names>JA</given-names></name>, <name><surname>Baum</surname><given-names>MM</given-names></name>. <chapter-title>Microbicide Vaginal Rings</chapter-title> In: <name><surname>das Neves</surname><given-names>J</given-names></name>, <name><surname>Sarmento</surname><given-names>B</given-names></name>, editors. <source>Drug Delivery and Development of Anti-HIV Microbicides</source>. <publisher-loc>Singapore</publisher-loc>: <publisher-name>Pan Stanford Publishing</publisher-name>; <year>2014</year> p. <fpage>221</fpage>–<lpage>90</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0201952.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Moss</surname><given-names>JA</given-names></name>, <name><surname>Srinivasan</surname><given-names>P</given-names></name>, <name><surname>Smith</surname><given-names>TJ</given-names></name>, <name><surname>Butkyavichene</surname><given-names>I</given-names></name>, <name><surname>Lopez</surname><given-names>G</given-names></name>, <name><surname>Brooks</surname><given-names>AA</given-names></name>, <etal>et al</etal><article-title>Pharmacokinetics and Preliminary Safety Study of Pod-Intravaginal Rings Delivering Antiretroviral Combinations for HIV Prophylaxis in a Macaque Model</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>9</issue>):<fpage>5125</fpage>–<lpage>35</lpage>. PubMed Central PMCID: PMCPMC4135875. <pub-id pub-id-type="doi">10.1128/AAC.02871-14</pub-id>
<?supplied-pmid 24936594?><pub-id pub-id-type="pmid">24936594</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Moss</surname><given-names>JA</given-names></name>, <name><surname>Butkyavichene</surname><given-names>I</given-names></name>, <name><surname>Churchman</surname><given-names>SA</given-names></name>, <name><surname>Gunawardana</surname><given-names>M</given-names></name>, <name><surname>Fanter</surname><given-names>R</given-names></name>, <name><surname>Miller</surname><given-names>CS</given-names></name>, <etal>et al</etal><article-title>Combination Pod-intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2016</year>;<volume>60</volume>(<issue>6</issue>):<fpage>3759</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00391-16</pub-id>
<?supplied-pmid 27067321?><pub-id pub-id-type="pmid">27067321</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Montgomery</surname><given-names>ET</given-names></name>, <name><surname>van der Straten</surname><given-names>A</given-names></name>, <name><surname>Cheng</surname><given-names>H</given-names></name>, <name><surname>Wegner</surname><given-names>L</given-names></name>, <name><surname>Masenga</surname><given-names>G</given-names></name>, <name><surname>von Mollendorf</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Vaginal Ring Adherence in Sub-Saharan Africa: Expulsion, Removal, and Perfect Use</article-title>. <source>AIDS Behav</source>. <year>2012</year>;<volume>16</volume>(<issue>7</issue>):<fpage>1787</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1007/s10461-012-0248-4</pub-id>
<?supplied-pmid 22790902?><pub-id pub-id-type="pmid">22790902</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Baum</surname><given-names>MM</given-names></name>, <name><surname>Butkyavichene</surname><given-names>I</given-names></name>, <name><surname>Gilman</surname><given-names>J</given-names></name>, <name><surname>Kennedy</surname><given-names>S</given-names></name>, <name><surname>Kopin</surname><given-names>E</given-names></name>, <name><surname>Malone</surname><given-names>AM</given-names></name>, <etal>et al</etal><article-title>An Intravaginal Ring for the Simultaneous Delivery of Multiple Drugs</article-title>. <source>J Pharm Sci</source>. <year>2012</year>;<volume>101</volume>(<issue>8</issue>):<fpage>2833</fpage>–<lpage>43</lpage>. PubMed Central PMCID: PMCPMC3857731. <pub-id pub-id-type="doi">10.1002/jps.23208</pub-id>
<?supplied-pmid 22619076?><pub-id pub-id-type="pmid">22619076</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Moss</surname><given-names>JA</given-names></name>, <name><surname>Baum</surname><given-names>MM</given-names></name>, <name><surname>Malone</surname><given-names>AM</given-names></name>, <name><surname>Kennedy</surname><given-names>S</given-names></name>, <name><surname>Kopin</surname><given-names>E</given-names></name>, <name><surname>Nguyen</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Tenofovir and Tenofovir Disoproxil Pharmacokinetics from Intravaginal Rings</article-title>. <source>Aids</source>. <year>2012</year>;<volume>26</volume>(<issue>6</issue>):<fpage>707</fpage>–<lpage>10</lpage>. PubMed Central PMCID: PMCPMC3855348. <pub-id pub-id-type="doi">10.1097/QAD.0b013e3283509abb</pub-id>
<?supplied-pmid 22210639?><pub-id pub-id-type="pmid">22210639</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Moss</surname><given-names>JA</given-names></name>, <name><surname>Malone</surname><given-names>AM</given-names></name>, <name><surname>Smith</surname><given-names>TJ</given-names></name>, <name><surname>Butkyavichene</surname><given-names>I</given-names></name>, <name><surname>Cortez</surname><given-names>C</given-names></name>, <name><surname>Gilman</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Safety and Pharmacokinetics of Intravaginal Rings Delivering Tenofovir in Pig-tailed Macaques</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2012</year>;<volume>56</volume>(<issue>11</issue>):<fpage>5952</fpage>–<lpage>60</lpage>. PubMed Central PMCID: PMCPMC3486594. <pub-id pub-id-type="doi">10.1128/AAC.01198-12</pub-id>
<?supplied-pmid 22964245?><pub-id pub-id-type="pmid">22964245</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Moss</surname><given-names>JA</given-names></name>, <name><surname>Malone</surname><given-names>AM</given-names></name>, <name><surname>Smith</surname><given-names>TJ</given-names></name>, <name><surname>Kennedy</surname><given-names>S</given-names></name>, <name><surname>Kopin</surname><given-names>E</given-names></name>, <name><surname>Nguyen</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Simultaneous Delivery of Tenofovir and Acyclovir via an Intravaginal Ring</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2012</year>;<volume>56</volume>(<issue>2</issue>):<fpage>875</fpage>–<lpage>82</lpage>. PubMed Central PMCID: PMCPMC3264253. <pub-id pub-id-type="doi">10.1128/AAC.05662-11</pub-id>
<?supplied-pmid 22123689?><pub-id pub-id-type="pmid">22123689</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Vincent</surname><given-names>KL</given-names></name>, <name><surname>Moss</surname><given-names>JA</given-names></name>, <name><surname>Marzinke</surname><given-names>MA</given-names></name>, <name><surname>Hendrix</surname><given-names>CW</given-names></name>, <name><surname>Anton</surname><given-names>PA</given-names></name>, <name><surname>Pyles</surname><given-names>RB</given-names></name>, <etal>et al</etal><article-title>Phase I Trial of Pod-intravaginal Rings Delivering Antiretroviral Agents for HIV-1 Prevention: Safety and Pharmacokinetics of Single (TDF), Dual (TDF-FTC), and Triple (TDF-FTC-MVC) Drug Formulations</article-title>. <source>PLoS Med</source>. <year>2018</year>:under review.</mixed-citation>
              </ref>
              <ref id="pone.0201952.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Nuttall</surname><given-names>J</given-names></name>, <name><surname>Kashuba</surname><given-names>A</given-names></name>, <name><surname>Wang</surname><given-names>R</given-names></name>, <name><surname>White</surname><given-names>N</given-names></name>, <name><surname>Allen</surname><given-names>P</given-names></name>, <name><surname>Roberts</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2012</year>;<volume>56</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00597-11</pub-id>
<?supplied-pmid 21986823?><pub-id pub-id-type="pmid">21986823</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Hendrix</surname><given-names>CW</given-names></name>, <name><surname>Chen</surname><given-names>BA</given-names></name>, <name><surname>Guddera</surname><given-names>V</given-names></name>, <name><surname>Hoesley</surname><given-names>C</given-names></name>, <name><surname>Justman</surname><given-names>J</given-names></name>, <name><surname>Nakabiito</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>MTN-001: Randomized Pharmacokinetic Cross-over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>1</issue>):<fpage>e55013</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0055013</pub-id> PubMed PMID: WOS:000315563800104. <?supplied-pmid 23383037?><pub-id pub-id-type="pmid">23383037</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Holt</surname><given-names>JD</given-names></name>, <name><surname>Cameron</surname><given-names>D</given-names></name>, <name><surname>Dias</surname><given-names>N</given-names></name>, <name><surname>Holding</surname><given-names>J</given-names></name>, <name><surname>Muntendam</surname><given-names>A</given-names></name>, <name><surname>Oostebring</surname><given-names>F</given-names></name>, <etal>et al</etal><article-title>The Sheep as a Model of Preclinical Safety and Pharmacokinetic Evaluations of Candidate Microbicides</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>7</issue>):<fpage>3761</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.04954-14</pub-id>
<?supplied-pmid 25845860?><pub-id pub-id-type="pmid">25845860</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref013">
                <label>13</label>
                <mixed-citation publication-type="other">Nair G, Justman JE, Piper J, Marzinke M, Hendrix C, Dai J, et al., editors. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: a Cross-compartmental Study with Directly Observed Dosing. 8th IAS Conference on Pathogenesis Treatment &amp; Prevention; 2015 July 21; Vancouver, Canada.</mixed-citation>
              </ref>
              <ref id="pone.0201952.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Keller</surname><given-names>MJ</given-names></name>, <name><surname>Mesquita</surname><given-names>PM</given-names></name>, <name><surname>Marzinke</surname><given-names>MA</given-names></name>, <name><surname>Teller</surname><given-names>R</given-names></name>, <name><surname>Espinoza</surname><given-names>L</given-names></name>, <name><surname>Atrio</surname><given-names>JM</given-names></name>, <etal>et al</etal><article-title>A Phase 1 Randomized Placebo-controlled Safety and Pharmacokinetic Trial of a Tenofovir Disoproxil Fumarate Vaginal Ring</article-title>. <source>Aids</source>. <year>2016</year>;<volume>30</volume>(<issue>5</issue>):<fpage>743</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0000000000000979</pub-id> PubMed PMID: WOS:000371309700001. <?supplied-pmid 26605514?><pub-id pub-id-type="pmid">26605514</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Javanbakht</surname><given-names>M</given-names></name>, <name><surname>Guerry</surname><given-names>S</given-names></name>, <name><surname>Gorbach</surname><given-names>PM</given-names></name>, <name><surname>Stirland</surname><given-names>A</given-names></name>, <name><surname>Chien</surname><given-names>M</given-names></name>, <name><surname>Anton</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>Prevalence and Correlates of Heterosexual Anal Intercourse Among Clients Attending Public Sexually Transmitted Disease Clinics in Los Angeles County</article-title>. <source>Sex Transm Dis</source>. <year>2010</year>;<volume>37</volume>(<issue>6</issue>):<fpage>369</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1097/OLQ.0b013e3181cbf77d</pub-id> PubMed PMID: WOS:000278379700007. <?supplied-pmid 20514690?><pub-id pub-id-type="pmid">20514690</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Gorbach</surname><given-names>PM</given-names></name>, <name><surname>Pines</surname><given-names>H</given-names></name>, <name><surname>Javanbakht</surname><given-names>M</given-names></name>, <name><surname>Weiss</surname><given-names>RE</given-names></name>, <name><surname>Jeffries</surname><given-names>R</given-names></name>, <name><surname>Cranston</surname><given-names>RD</given-names></name>, <etal>et al</etal><article-title>Order of Orifices: Sequence of Condom Use and Ejaculation by Orifice During Anal Intercourse Among Women: Implications for HIV Transmission</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2014</year>;<volume>67</volume>(<issue>4</issue>):<fpage>424</fpage>–<lpage>9</lpage>. PubMed PMID: WOS:000344771900015. <pub-id pub-id-type="doi">10.1097/QAI.0000000000000314</pub-id>
<?supplied-pmid 25356778?><pub-id pub-id-type="pmid">25356778</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Owen</surname><given-names>BN</given-names></name>, <name><surname>Brock</surname><given-names>PM</given-names></name>, <name><surname>Butler</surname><given-names>AR</given-names></name>, <name><surname>Pickles</surname><given-names>M</given-names></name>, <name><surname>Brisson</surname><given-names>M</given-names></name>, <name><surname>Baggaley</surname><given-names>RF</given-names></name>, <etal>et al</etal><article-title>Prevalence and Frequency of Heterosexual Anal Intercourse Among Young People: A Systematic Review and Meta-analysis</article-title>. <source>AIDS Behav</source>. <year>2015</year>;<volume>19</volume>(<issue>7</issue>):<fpage>1338</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s10461-015-0997-y</pub-id> PubMed PMID: WOS:000358248600018. <?supplied-pmid 25618257?><pub-id pub-id-type="pmid">25618257</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Anton</surname><given-names>PA</given-names></name>, <name><surname>Cranston</surname><given-names>RD</given-names></name>, <name><surname>Kashuba</surname><given-names>A</given-names></name>, <name><surname>Hendrix</surname><given-names>CW</given-names></name>, <name><surname>Bumpus</surname><given-names>NN</given-names></name>, <name><surname>Richardson-Harman</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate</article-title>. <source>AIDS Res Hum Retrovir</source>. <year>2012</year>;<volume>28</volume>(<issue>11</issue>):<fpage>1412</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2012.0262</pub-id> PubMed PMID: WOS:000310754100006. <?supplied-pmid 22943559?><pub-id pub-id-type="pmid">22943559</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Richardson-Harman</surname><given-names>N</given-names></name>, <name><surname>Mauck</surname><given-names>C</given-names></name>, <name><surname>McGowan</surname><given-names>I</given-names></name>, <name><surname>Anton</surname><given-names>P</given-names></name>. <article-title>Dose-response Relationship Between Tissue Concentrations of UC781 and Explant Infectibility with HIV Type 1 in the RMP-01 Rectal Safety Study</article-title>. <source>AIDS Res Hum Retrovir</source>. <year>2012</year>;<volume>28</volume>(<issue>11</issue>):<fpage>1422</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2012.0073</pub-id> PubMed PMID: WOS:000310754100007. <?supplied-pmid 22900504?><pub-id pub-id-type="pmid">22900504</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>KH</given-names></name>, <name><surname>Elliot</surname><given-names>J</given-names></name>, <name><surname>Hendrix</surname><given-names>C</given-names></name>, <name><surname>Anton</surname><given-names>P</given-names></name>, <name><surname>Cranston</surname><given-names>R</given-names></name>, <name><surname>McGowan</surname><given-names>I</given-names></name>, <etal>et al</etal><article-title>Population PK Model of Rectal 1% Tenofovir (TFV) Gel in the Rectum and Plasma</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2013</year>;<volume>40</volume>:<fpage>S146</fpage>–<lpage>S8</lpage>. PubMed PMID: WOS:000330126000159.</mixed-citation>
              </ref>
              <ref id="pone.0201952.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>McGowan</surname><given-names>I</given-names></name>, <name><surname>Cranston</surname><given-names>RD</given-names></name>, <name><surname>Duffill</surname><given-names>K</given-names></name>, <name><surname>Siegel</surname><given-names>A</given-names></name>, <name><surname>Engstrom</surname><given-names>JC</given-names></name>, <name><surname>Nikiforov</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e0125363</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0125363</pub-id> PubMed PMID: WOS:000353943400032. <?supplied-pmid 25942472?><pub-id pub-id-type="pmid">25942472</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Bunge</surname><given-names>KE</given-names></name>, <name><surname>Dezzutti</surname><given-names>CS</given-names></name>, <name><surname>Rohan</surname><given-names>LC</given-names></name>, <name><surname>Hendrix</surname><given-names>CW</given-names></name>, <name><surname>Marzinke</surname><given-names>MA</given-names></name>, <name><surname>Richardson-Harman</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2016</year>;<volume>71</volume>(<issue>5</issue>):<fpage>498</fpage>–<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0000000000000897</pub-id> PubMed PMID: WOS:000372350300005. <?supplied-pmid 26565716?><pub-id pub-id-type="pmid">26565716</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Dezzutti</surname><given-names>CS</given-names></name>, <name><surname>Richardson-Harman</surname><given-names>N</given-names></name>, <name><surname>Rohan</surname><given-names>LC</given-names></name>, <name><surname>Marzinke</surname><given-names>MA</given-names></name>, <name><surname>Hoesley</surname><given-names>CJ</given-names></name>, <name><surname>Panther</surname><given-names>L</given-names></name>, <etal>et al</etal><article-title>Pharmacodynamic Correlations Using Fresh and Cryopreserved Tissue Following Use of Vaginal Rings Containing Dapivirine and/or Maraviroc in a Randomized, Placebo Controlled Trial</article-title>. <source>Medicine (Baltimore)</source>. <year>2016</year>;<volume>95</volume>(<issue>28</issue>). <pub-id pub-id-type="doi">10.1097/md.0000000000004174</pub-id> PubMed PMID: WOS:000380767200034. <?supplied-pmid 27428211?><pub-id pub-id-type="pmid">27428211</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>McGowan</surname><given-names>I</given-names></name>, <name><surname>Dezzutti</surname><given-names>CS</given-names></name>, <name><surname>Siegel</surname><given-names>A</given-names></name>, <name><surname>Engstrom</surname><given-names>J</given-names></name>, <name><surname>Nikiforov</surname><given-names>A</given-names></name>, <name><surname>Duffill</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>Long-acting Rilpivirine as Potential Pre-exposure Prophylaxis for HIV-1 Prevention (the MWRI-01 study): an Open-label, Phase 1, Compartmental, Pharmacokinetic and Pharmacodynamic Assessment</article-title>. <source>Lancet HIV</source>. <year>2016</year>;<volume>3</volume>(<issue>12</issue>):<fpage>E569</fpage>–<lpage>E78</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-3018(16)30113-8</pub-id> PubMed PMID: WOS:000389072800011. <?supplied-pmid 27658864?><pub-id pub-id-type="pmid">27658864</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Richardson-Harman</surname><given-names>N</given-names></name>, <name><surname>Parody</surname><given-names>R</given-names></name>, <name><surname>Anton</surname><given-names>P</given-names></name>, <name><surname>McGowan</surname><given-names>I</given-names></name>, <name><surname>Doncel</surname><given-names>G</given-names></name>, <name><surname>Thurman</surname><given-names>AR</given-names></name>, <etal>et al</etal><article-title>Analytical Advances in the <italic>Ex Vivo</italic> Challenge Efficacy Assay</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2016</year>:Epub ahead of print Dec. 16.</mixed-citation>
              </ref>
              <ref id="pone.0201952.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Robinson</surname><given-names>JA</given-names></name>, <name><surname>Marzinke</surname><given-names>MA</given-names></name>, <name><surname>Bakshi</surname><given-names>RP</given-names></name>, <name><surname>Fuchs</surname><given-names>EJ</given-names></name>, <name><surname>Radebaugh</surname><given-names>CL</given-names></name>, <name><surname>Aung</surname><given-names>W</given-names></name>, <etal>et al</etal><article-title>Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B)</article-title>. <source>AIDS Res Hum Retrovir</source>. <year>2017</year>;<volume>33</volume>(<issue>4</issue>):<fpage>339</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2016.0040</pub-id> PubMed PMID: WOS:000397584200008. <?supplied-pmid 27809557?><pub-id pub-id-type="pmid">27809557</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Baum</surname><given-names>MM</given-names></name>, <name><surname>Butkyavichene</surname><given-names>I</given-names></name>, <name><surname>Churchman</surname><given-names>SA</given-names></name>, <name><surname>Lopez</surname><given-names>G</given-names></name>, <name><surname>Miller</surname><given-names>CS</given-names></name>, <name><surname>Smith</surname><given-names>TJ</given-names></name>, <etal>et al</etal><article-title>An Intravaginal Ring for the Sustained Delivery of Tenofovir Disoproxil Fumarate</article-title>. <source>Int J Pharm</source>. <year>2015</year>;<volume>495</volume>(<issue>1</issue>):<fpage>579</fpage>–<lpage>87</lpage>. PubMed Central PMCID: PMCPMCID: PMC4609628. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2015.09.028</pub-id>
<?supplied-pmid 26386138?><pub-id pub-id-type="pmid">26386138</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Parsons</surname><given-names>TL</given-names></name>, <name><surname>Emory</surname><given-names>JF</given-names></name>, <name><surname>Seserko</surname><given-names>LA</given-names></name>, <name><surname>Aung</surname><given-names>WS</given-names></name>, <name><surname>Marzinke</surname><given-names>MA</given-names></name>. <article-title>Dual Quantification of Dapivirine and Maraviroc in Cervicovaginal Secretions from Ophthalmic Tear Strips and Polyester-based Swabs via Liquid Chromatographic-tandem Mass Spectrometric (LC-MS/MS) Analysis</article-title>. <source>J Pharm Biomed Anal</source>. <year>2014</year>;<volume>98</volume>:<fpage>407</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpba.2014.06.018</pub-id> PubMed PMID: WOS:000339859800055. <?supplied-pmid 25005891?><pub-id pub-id-type="pmid">25005891</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Hendrix</surname><given-names>CW</given-names></name>, <name><surname>Andrade</surname><given-names>A</given-names></name>, <name><surname>Bumpus</surname><given-names>NN</given-names></name>, <name><surname>Kashuba</surname><given-names>AD</given-names></name>, <name><surname>Marzinke</surname><given-names>MA</given-names></name>, <name><surname>Moore</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)</article-title>. <source>AIDS Res Hum Retrovir</source>. <year>2016</year>;<volume>32</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2015.0182</pub-id> PubMed PMID: WOS:000367335100006. <?supplied-pmid 26414912?><pub-id pub-id-type="pmid">26414912</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Parsons</surname><given-names>TL</given-names></name>, <name><surname>Marzinke</surname><given-names>MA</given-names></name>. <article-title>Development and Validation of a Liquid Chromatographic-tandem Mass Spectrometric Method for the Multiplexed Quantification of Etravirine, Maraviroc, Raltegravir, and Rilpivirine in Human Plasma and Tissue</article-title>. <source>J Pharm Biomed Anal</source>. <year>2016</year>;<volume>131</volume>:<fpage>333</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpba.2016.08.016</pub-id> PubMed PMID: WOS:000387628400044. <?supplied-pmid 27632783?><pub-id pub-id-type="pmid">27632783</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref031">
                <label>31</label>
                <mixed-citation publication-type="other">US FDA. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2001 May. Report No.</mixed-citation>
              </ref>
              <ref id="pone.0201952.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Robbins</surname><given-names>BL</given-names></name>, <name><surname>Srinivas</surname><given-names>RV</given-names></name>, <name><surname>Kim</surname><given-names>C</given-names></name>, <name><surname>Bischofberger</surname><given-names>N</given-names></name>, <name><surname>Fridland</surname><given-names>A</given-names></name>. <article-title>Anti-human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1998</year>;<volume>42</volume>(<issue>3</issue>):<fpage>612</fpage>–<lpage>7</lpage>. PubMed PMID: WOS:000072311000021. <?supplied-pmid 9517941?><pub-id pub-id-type="pmid">9517941</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Arimilli</surname><given-names>MN</given-names></name>, <name><surname>Kim</surname><given-names>CU</given-names></name>, <name><surname>Dougherty</surname><given-names>J</given-names></name>, <name><surname>Mulato</surname><given-names>A</given-names></name>, <name><surname>Oliyai</surname><given-names>R</given-names></name>, <name><surname>Shaw</surname><given-names>JP</given-names></name>, <etal>et al</etal><article-title>Synthesis, in Vitro Biological Evaluation and Oral Bioavailability of 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Prodrugs</article-title>. <source>Antivir Chem Chemother</source>. <year>1997</year>;<volume>8</volume>(<issue>6</issue>):<fpage>557</fpage>–<lpage>64</lpage>. PubMed PMID: ISI:A1997YJ91700010.</mixed-citation>
              </ref>
              <ref id="pone.0201952.ref034">
                <label>34</label>
                <mixed-citation publication-type="other">TRUVADA (Emtricitabine and Tenofovir Disoproxil Fumarate) Silver Spring, MD: U.S. Food and Drug Administration; [cited 2014 Oct. 14]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021752s043lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021752s043lbl.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0201952.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>LH</given-names></name>, <name><surname>Begley</surname><given-names>J</given-names></name>, <name><surname>St Claire</surname><given-names>RL</given-names></name>, <name><surname>Harris</surname><given-names>J</given-names></name>, <name><surname>Wakeford</surname><given-names>C</given-names></name>, <name><surname>Rousseau</surname><given-names>FS</given-names></name>. <article-title>Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV Infection</article-title>. <source>AIDS Res Hum Retrovir</source>. <year>2004</year>;<volume>20</volume>(<issue>11</issue>):<fpage>1173</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2004.20.1173</pub-id> PubMed PMID: WOS:000225576400005. <?supplied-pmid 15588339?><pub-id pub-id-type="pmid">15588339</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>L</given-names></name>, <name><surname>Peterson</surname><given-names>S</given-names></name>, <name><surname>Sedaghat</surname><given-names>AR</given-names></name>, <name><surname>McMahon</surname><given-names>MA</given-names></name>, <name><surname>Callender</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>HL</given-names></name>, <etal>et al</etal><article-title>Dose-response Curve Slope Sets Class-specific Limits on Inhibitory Potential of Anti-HIV Drugs</article-title>. <source>Nature Med</source>. <year>2008</year>;<volume>14</volume>(<issue>7</issue>):<fpage>762</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nm1777</pub-id> PubMed PMID: WOS:000257452700024. <?supplied-pmid 18552857?><pub-id pub-id-type="pmid">18552857</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Jilek</surname><given-names>BL</given-names></name>, <name><surname>Zarr</surname><given-names>M</given-names></name>, <name><surname>Sampah</surname><given-names>ME</given-names></name>, <name><surname>Rabi</surname><given-names>SA</given-names></name>, <name><surname>Bullen</surname><given-names>CK</given-names></name>, <name><surname>Lai</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>A Quantitative Basis for Antiretroviral Therapy for HIV-1</article-title><source>Infection. Nat Med</source>. <year>2012</year>;<volume>18</volume>(<issue>3</issue>):<fpage>446</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2649</pub-id>
<?supplied-pmid 22344296?><pub-id pub-id-type="pmid">22344296</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Agosto</surname><given-names>LM</given-names></name>, <name><surname>Zhong</surname><given-names>P</given-names></name>, <name><surname>Munro</surname><given-names>J</given-names></name>, <name><surname>Mothes</surname><given-names>W</given-names></name>. <article-title>Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission</article-title>. <source>PLoS Pathog</source>. <year>2014</year>;<volume>10</volume>(<issue>2</issue>):<fpage>e1003982</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003982</pub-id> PubMed PMID: WOS:000332085900053. <?supplied-pmid 24586176?><pub-id pub-id-type="pmid">24586176</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Dorr</surname><given-names>P</given-names></name>, <name><surname>Westby</surname><given-names>M</given-names></name>, <name><surname>Dobbs</surname><given-names>S</given-names></name>, <name><surname>Griffin</surname><given-names>P</given-names></name>, <name><surname>Irvine</surname><given-names>B</given-names></name>, <name><surname>Macartney</surname><given-names>M</given-names></name>, <etal>et al</etal> Maraviroc (UK-427,857), <article-title>a Potent, Orally Bioavailable, and Selective Small-molecule Inhibitor of Chemokine Receptor CCR5 with Broad-spectrum Anti-human Immunodeficiency Virus Type 1 Activity</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2005</year>;<volume>49</volume>(<issue>11</issue>):<fpage>4721</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.49.11.4721-4732.2005</pub-id> PubMed PMID: ISI:000233020900039. <?supplied-pmid 16251317?><pub-id pub-id-type="pmid">16251317</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Kis</surname><given-names>O</given-names></name>, <name><surname>Robillard</surname><given-names>K</given-names></name>, <name><surname>Chan</surname><given-names>GNY</given-names></name>, <name><surname>Bendayan</surname><given-names>R</given-names></name>. <article-title>The Complexities of Antiretroviral Drug-drug Interactions: Role of ABC and SLC Transporters</article-title>. <source>Trends Pharmacol Sci</source>. <year>2010</year>;<volume>31</volume>(<issue>1</issue>):<fpage>22</fpage>–<lpage>35</lpage>. PubMed PMID: WOS:000274377700005. <pub-id pub-id-type="doi">10.1016/j.tips.2009.10.001</pub-id>
<?supplied-pmid 20004485?><pub-id pub-id-type="pmid">20004485</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0201952.ref041">
                <label>41</label>
                <mixed-citation publication-type="book"><name><surname>Pyles</surname><given-names>RB</given-names></name>, <name><surname>Moss</surname><given-names>JA</given-names></name>, <name><surname>Baum</surname><given-names>MM</given-names></name>. <chapter-title>Vaginal Mucosal HIV Prep: Fundamental Insights and Practical Considerations</chapter-title><year>2015</year> In: <source>Frontiers in Clinical Drug Research</source>: HIV [Internet]. <publisher-loc>Oak Park, IL</publisher-loc>: <publisher-name>Bentham Science Publishers</publisher-name>; [33–165].</mixed-citation>
              </ref>
              <ref id="pone.0201952.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Weld</surname><given-names>ED</given-names></name>, <name><surname>Hiruy</surname><given-names>H</given-names></name>, <name><surname>Guthrie</surname><given-names>KM</given-names></name>, <name><surname>Fava</surname><given-names>JL</given-names></name>, <name><surname>Vargas</surname><given-names>SE</given-names></name>, <name><surname>Buckheit</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability</article-title>. <source>AIDS Res Hum Retrovir</source>. <year>2017</year>;<volume>33</volume>(<issue>5</issue>):<fpage>440</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1089/AID.2016.0167</pub-id>
<?supplied-pmid 27824253?><pub-id pub-id-type="pmid">27824253</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
